Ontology type: schema:ScholarlyArticle Open Access: True
2021-09-17
AUTHORSKatsutoshi Tokushige, Kenichi Ikejima, Masafumi Ono, Yuichiro Eguchi, Yoshihiro Kamada, Yoshito Itoh, Norio Akuta, Masato Yoneda, Motoh Iwasa, Masashi Yoneda, Motoyuki Otsuka, Nobuharu Tamaki, Tomomi Kogiso, Hiroto Miwa, Kazuaki Chayama, Nobuyuki Enomoto, Tooru Shimosegawa, Tetsuo Takehara, Kazuhiko Koike
ABSTRACTNonalcoholic fatty liver disease (NAFLD) has become a serious public health issue not only in Western countries but also in Japan. Within the wide spectrum of NAFLD, nonalcoholic steatohepatitis (NASH) is a progressive form of disease that often develops into liver cirrhosis and increases the risk of hepatocellular carcinoma (HCC). While a definite diagnosis of NASH requires liver biopsy to confirm the presence of hepatocyte ballooning, hepatic fibrosis is the most important prognostic factor in NAFLD. With so many NAFLD patients, it is essential to have an effective screening method for NAFLD with hepatic fibrosis. As HCC with non-viral liver disease has increased markedly in Japan, effective screening and surveillance of HCC are also urgently needed. The most common death etiology in NAFLD patients is cardiovascular disease (CVD) event. Gastroenterologists must, therefore, pay close attention to CVD when examining NAFLD patients. In the updated guidelines, we propose screening and follow-up methods for hepatic fibrosis, HCC, and CVD in NAFLD patients. Several drug trials are ongoing for NAFLD/NASH therapy, however, there is currently no specific drug therapy for NAFLD/NASH. In addition to vitamin E and thiazolidinedione derivatives, recent trials have focused on sodium glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) analogues, and effective therapies are expected to be developed. These practical guidelines for NAFLD/NASH were established by the Japanese Society of Gastroenterology in conjunction with the Japan Society of Hepatology. Clinical evidence reported internationally between 1983 and October 2018 was collected, and each clinical and background question was evaluated using the Grades of Recommendation Assessment, Development and Evaluation (GRADE) system. This English summary provides the core essentials of these clinical practice guidelines, which include the definition and concept, screening systems for hepatic fibrosis, HCC and CVD, and current therapies for NAFLD/NASH in Japan. More... »
PAGES951-963
http://scigraph.springernature.com/pub.10.1007/s00535-021-01796-x
DOIhttp://dx.doi.org/10.1007/s00535-021-01796-x
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1141192505
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/34533632
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Cardiorespiratory Medicine and Haematology",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Disease Progression",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Evidence-Based Practice",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Guidelines as Topic",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Japan",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Non-alcoholic Fatty Liver Disease",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Institute of Gastroenterology, Department of Internal Medicine, Tokyo Women\u2019s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/grid.410818.4",
"name": [
"Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan",
"Institute of Gastroenterology, Department of Internal Medicine, Tokyo Women\u2019s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Tokushige",
"givenName": "Katsutoshi",
"id": "sg:person.01161346545.50",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01161346545.50"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Ikejima",
"givenName": "Kenichi",
"id": "sg:person.0607415435.38",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0607415435.38"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Ono",
"givenName": "Masafumi",
"id": "sg:person.01077500221.35",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01077500221.35"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Eguchi",
"givenName": "Yuichiro",
"id": "sg:person.0617655144.72",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617655144.72"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Kamada",
"givenName": "Yoshihiro",
"id": "sg:person.01052677526.47",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052677526.47"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Itoh",
"givenName": "Yoshito",
"id": "sg:person.01017130226.32",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017130226.32"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Akuta",
"givenName": "Norio",
"id": "sg:person.01111770263.06",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01111770263.06"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Yoneda",
"givenName": "Masato",
"id": "sg:person.011766317402.99",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011766317402.99"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Iwasa",
"givenName": "Motoh",
"id": "sg:person.01105625564.62",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01105625564.62"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Yoneda",
"givenName": "Masashi",
"id": "sg:person.013606074302.33",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013606074302.33"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Otsuka",
"givenName": "Motoyuki",
"id": "sg:person.01315063735.13",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01315063735.13"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Tamaki",
"givenName": "Nobuharu",
"id": "sg:person.0603023143.36",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603023143.36"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Kogiso",
"givenName": "Tomomi",
"id": "sg:person.01173722134.47",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173722134.47"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Miwa",
"givenName": "Hiroto",
"id": "sg:person.0611747536.16",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611747536.16"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "The Japan Society of Hepatology, Kashiwaya 2 Building 5F, 3-28-10 Hongo, Bunkyo-ku, 113-0033, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/None",
"name": [
"The Japan Society of Hepatology, Kashiwaya 2 Building 5F, 3-28-10 Hongo, Bunkyo-ku, 113-0033, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Chayama",
"givenName": "Kazuaki",
"id": "sg:person.01277325545.79",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01277325545.79"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Enomoto",
"givenName": "Nobuyuki",
"id": "sg:person.01353463070.60",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01353463070.60"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Shimosegawa",
"givenName": "Tooru",
"id": "sg:person.01255535707.76",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255535707.76"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "The Japan Society of Hepatology, Kashiwaya 2 Building 5F, 3-28-10 Hongo, Bunkyo-ku, 113-0033, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/None",
"name": [
"The Japan Society of Hepatology, Kashiwaya 2 Building 5F, 3-28-10 Hongo, Bunkyo-ku, 113-0033, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Takehara",
"givenName": "Tetsuo",
"id": "sg:person.01207223634.98",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01207223634.98"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Guidelines Committee for Creating and Evaluating the \u2018\u2018Evidence-Based Clinical Practice Guidelines for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis\u2019\u2019, The Japanese Society of Gastroenterology / The Japan Society of Hepatology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, 105-0004, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Koike",
"givenName": "Kazuhiko",
"id": "sg:person.01231713652.67",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01231713652.67"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1038/nature04634",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1030208897",
"https://doi.org/10.1038/nature04634"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/nrgastro.2017.109",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1091858590",
"https://doi.org/10.1038/nrgastro.2017.109"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00535-015-1050-7",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1032449418",
"https://doi.org/10.1007/s00535-015-1050-7"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00125-011-2446-4",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1021177494",
"https://doi.org/10.1007/s00125-011-2446-4"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1186/1471-230x-12-2",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1028332469",
"https://doi.org/10.1186/1471-230x-12-2"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s12072-014-9605-x",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1008920821",
"https://doi.org/10.1007/s12072-014-9605-x"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/nature10809",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1022220176",
"https://doi.org/10.1038/nature10809"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/ajg.2011.327",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1045853983",
"https://doi.org/10.1038/ajg.2011.327"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/ng.257",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1045345124",
"https://doi.org/10.1038/ng.257"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/s41598-017-04991-0",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1087302773",
"https://doi.org/10.1038/s41598-017-04991-0"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/s41598-020-57935-6",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1124223309",
"https://doi.org/10.1038/s41598-020-57935-6"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00535-017-1364-8",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1090324716",
"https://doi.org/10.1007/s00535-017-1364-8"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/ng.2901",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1008453458",
"https://doi.org/10.1038/ng.2901"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00535-018-1474-y",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1103901166",
"https://doi.org/10.1007/s00535-018-1474-y"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00535-010-0311-8",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1038400215",
"https://doi.org/10.1007/s00535-010-0311-8"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00535-011-0436-4",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1004332631",
"https://doi.org/10.1007/s00535-011-0436-4"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/ajg.2016.453",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1006298465",
"https://doi.org/10.1038/ajg.2016.453"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00535-012-0533-z",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1009954415",
"https://doi.org/10.1007/s00535-012-0533-z"
],
"type": "CreativeWork"
}
],
"datePublished": "2021-09-17",
"datePublishedReg": "2021-09-17",
"description": "Nonalcoholic fatty liver disease (NAFLD) has become a serious public health issue not only in Western countries but also in Japan. Within the wide spectrum of NAFLD, nonalcoholic steatohepatitis (NASH) is a progressive form of disease that often develops into liver cirrhosis and increases the risk of hepatocellular carcinoma (HCC). While a definite diagnosis of NASH requires liver biopsy to confirm the presence of hepatocyte ballooning, hepatic fibrosis is the most important prognostic factor in NAFLD. With so many NAFLD patients, it is essential to have an effective screening method for NAFLD with hepatic fibrosis. As HCC with non-viral liver disease has increased markedly in Japan, effective screening and surveillance of HCC are also urgently needed. The most common death etiology in NAFLD patients is cardiovascular disease (CVD) event. Gastroenterologists must, therefore, pay close attention to CVD when examining NAFLD patients. In the updated guidelines, we propose screening and follow-up methods for hepatic fibrosis, HCC, and CVD in NAFLD patients. Several drug trials are ongoing for NAFLD/NASH therapy, however, there is currently no specific drug therapy for NAFLD/NASH. In addition to vitamin E and thiazolidinedione derivatives, recent trials have focused on sodium glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) analogues, and effective therapies are expected to be developed. These practical guidelines for NAFLD/NASH were established by the Japanese Society of Gastroenterology in conjunction with the Japan Society of Hepatology. Clinical evidence reported internationally between 1983 and October 2018 was collected, and each clinical and background question was evaluated using the Grades of Recommendation Assessment, Development and Evaluation (GRADE) system. This English summary provides the core essentials of these clinical practice guidelines, which include the definition and concept, screening systems for hepatic fibrosis, HCC and CVD, and current therapies for NAFLD/NASH in Japan.",
"genre": "article",
"id": "sg:pub.10.1007/s00535-021-01796-x",
"isAccessibleForFree": true,
"isPartOf": [
{
"id": "sg:journal.1009747",
"issn": [
"0944-1174",
"1435-5922"
],
"name": "Journal of Gastroenterology",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "11",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "56"
}
],
"keywords": [
"nonalcoholic fatty liver disease",
"NAFLD/nonalcoholic steatohepatitis",
"nonalcoholic steatohepatitis",
"clinical practice guidelines",
"NAFLD patients",
"hepatocellular carcinoma",
"hepatic fibrosis",
"liver disease",
"practice guidelines",
"evidence-based clinical practice guidelines",
"glucagon-like peptide-1 analog",
"surveillance of HCC",
"non-viral liver disease",
"cardiovascular disease events",
"fatty liver disease",
"important prognostic factor",
"serious public health issue",
"peptide-1 analog",
"specific drug therapy",
"public health issue",
"Recommendations Assessment",
"hepatocyte ballooning",
"NAFLD/",
"liver cirrhosis",
"prognostic factors",
"liver biopsy",
"sodium glucose",
"clinical evidence",
"drug therapy",
"current therapies",
"definite diagnosis",
"recent trials",
"effective therapy",
"drug trials",
"disease events",
"effective screening method",
"vitamin E",
"patients",
"fibrosis",
"progressive form",
"therapy",
"health issues",
"disease",
"thiazolidinedione derivatives",
"effective screening",
"Western countries",
"trials",
"guidelines",
"Japan Society",
"wide spectrum",
"background questions",
"screening method",
"Japanese Society",
"steatohepatitis",
"cirrhosis",
"biopsy",
"gastroenterologists",
"carcinoma",
"CVD",
"Hepatology",
"etiology",
"gastroenterology",
"diagnosis",
"ballooning",
"core essentials",
"risk",
"surveillance",
"inhibitors",
"glucose",
"screening",
"practical guidelines",
"grade",
"evidence",
"assessment",
"English summaries",
"close attention",
"factors",
"Japan",
"summary",
"events",
"presence",
"evaluation system",
"analogues",
"addition",
"development",
"essential",
"countries",
"method",
"conjunction",
"society",
"definition",
"questions",
"system",
"form",
"attention",
"derivatives",
"issues",
"concept",
"spectra"
],
"name": "Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020",
"pagination": "951-963",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1141192505"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s00535-021-01796-x"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"34533632"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s00535-021-01796-x",
"https://app.dimensions.ai/details/publication/pub.1141192505"
],
"sdDataset": "articles",
"sdDatePublished": "2022-08-04T17:11",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_895.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s00535-021-01796-x"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00535-021-01796-x'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00535-021-01796-x'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00535-021-01796-x'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00535-021-01796-x'
This table displays all metadata directly associated to this object as RDF triples.
388 TRIPLES
21 PREDICATES
148 URIs
122 LITERALS
13 BLANK NODES